10:44:05 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande



2024-11-08 Kvartalsrapport 2024-Q3
2024-08-22 Kvartalsrapport 2024-Q2
2024-05-07 X-dag ordinarie utdelning EGTX 0.00 SEK
2024-05-06 Årsstämma 2024
2024-05-03 Kvartalsrapport 2024-Q1
2024-02-22 Bokslutskommuniké 2023
2023-11-08 Kvartalsrapport 2023-Q3
2023-08-22 Kvartalsrapport 2023-Q2
2023-04-28 X-dag ordinarie utdelning EGTX 0.00 SEK
2023-04-27 Årsstämma 2023
2023-04-26 Kvartalsrapport 2023-Q1
2023-02-22 Bokslutskommuniké 2022
2022-11-08 Kvartalsrapport 2022-Q3
2022-08-19 Kvartalsrapport 2022-Q2
2022-05-30 Årsstämma 2022
2022-05-11 X-dag ordinarie utdelning EGTX 0.00 SEK
2022-04-26 Kvartalsrapport 2022-Q1
2022-04-13 Extra Bolagsstämma 2022
2022-02-17 Bokslutskommuniké 2021
2021-11-04 Kvartalsrapport 2021-Q3
2021-08-19 Kvartalsrapport 2021-Q2
2021-04-30 X-dag ordinarie utdelning EGTX 0.00 SEK
2021-04-29 Årsstämma 2021
2021-04-22 Kvartalsrapport 2021-Q1
2021-02-17 Bokslutskommuniké 2020
2020-12-11 Extra Bolagsstämma 2020
2020-11-04 Kvartalsrapport 2020-Q3
2020-08-20 Kvartalsrapport 2020-Q2
2020-04-24 X-dag ordinarie utdelning EGTX 0.00 SEK
2020-04-23 Årsstämma 2020
2020-04-22 Kvartalsrapport 2020-Q1
2020-02-18 Bokslutskommuniké 2019
2019-10-23 Kvartalsrapport 2019-Q3
2019-08-21 Kvartalsrapport 2019-Q2
2019-05-08 X-dag ordinarie utdelning EGTX 0.00 SEK
2019-05-07 Årsstämma 2019
2019-05-06 Kvartalsrapport 2019-Q1
2019-02-21 Bokslutskommuniké 2018
2018-10-23 Kvartalsrapport 2018-Q3
2018-08-22 Kvartalsrapport 2018-Q2
2018-04-25 X-dag ordinarie utdelning EGTX 0.00 SEK
2018-04-24 Kvartalsrapport 2018-Q1
2018-04-24 Årsstämma 2018
2018-02-22 Bokslutskommuniké 2017
2017-10-20 Kvartalsrapport 2017-Q3
2017-08-30 Kvartalsrapport 2017-Q2
2017-04-26 X-dag ordinarie utdelning EGTX 0.00 SEK
2017-04-25 Årsstämma 2017
2017-04-25 Kvartalsrapport 2017-Q1
2017-02-24 Bokslutskommuniké 2016
2017-02-10 Extra Bolagsstämma 2017
2016-11-07 Extra Bolagsstämma 2016
2016-10-20 Kvartalsrapport 2016-Q3
2016-08-25 Kvartalsrapport 2016-Q2
2016-04-29 Kvartalsrapport 2016-Q1
2016-04-15 X-dag ordinarie utdelning EGTX 0.00 SEK
2016-04-14 Årsstämma 2016
2016-02-29 Bokslutskommuniké 2015
2015-10-20 Kvartalsrapport 2015-Q3
2015-08-18 Kvartalsrapport 2015-Q2
2015-04-21 Kvartalsrapport 2015-Q1
2015-04-15 X-dag ordinarie utdelning EGTX 0.00 SEK
2015-04-14 Årsstämma 2015
2015-02-17 Bokslutskommuniké 2014
2014-11-14 Extra Bolagsstämma 2014
2014-10-24 Kvartalsrapport 2014-Q3
2014-08-28 Kvartalsrapport 2014-Q2
2014-04-25 Kvartalsrapport 2014-Q1
2014-04-09 X-dag ordinarie utdelning EGTX 0.00 SEK
2014-04-08 Årsstämma 2014
2014-02-19 Bokslutskommuniké 2013
2013-10-25 Kvartalsrapport 2013-Q3
2013-08-29 Kvartalsrapport 2013-Q2
2013-04-19 X-dag ordinarie utdelning EGTX 0.00 SEK
2013-04-18 Kvartalsrapport 2013-Q1
2013-04-18 Årsstämma 2013
2013-04-18 Extra Bolagsstämma 2013
2013-03-13 15-7 2013
2013-02-21 Bokslutskommuniké 2012
2012-10-26 Kvartalsrapport 2012-Q3
2012-08-24 Kvartalsrapport 2012-Q2
2012-04-27 Kvartalsrapport 2012-Q1
2012-03-30 X-dag ordinarie utdelning EGTX 0.00 SEK
2012-03-29 Årsstämma 2012
2012-02-17 Bokslutskommuniké 2011
2011-10-27 Kvartalsrapport 2011-Q3
2011-08-25 Kvartalsrapport 2011-Q2
2011-05-12 Kvartalsrapport 2011-Q1


ListaSmall Cap Stockholm
Egetis Therapeutics är ett läkemedelsutvecklingsbolag. Bolagets huvudsakliga fokus är på projekt i sen klinisk utvecklingsfas inom särläkemedelsområdet för behandling av allvarliga och sällsynta sjukdomar med betydande medicinska behov. Exempel på bolagets läkemedelskandidater är Emcitate, som utvecklas för patienter med MCT8-brist och Aladote, som utvecklas för att reducera akuta leverskador.
2020-08-20 08:00:00

April-June • Quarterly net sales MSEK 21.7 (5.0) • Quarterly result MSEK till -36.2 (-29,4) • Cash and cash equivalents MSEK 184.5 (319.5) • Cash flow from operating activities MSEK -33.8 (59.3) • Result per share SEK -0.7 (-0.6)

· PledPharma decided to prematurely stop and read-out the POLAR phase III program with a data cut-off targeted for the third quarter 2020. The decision was taken after a recommendation from the independent Drug Safety Monitoring Board (DSMB) to stop the studies due to a few severe allergic reactions after repeated dosing
· Positive pre-clinical results presented at Peripheral Nerve Society’s annual meeting
· Interactions are ongoing with the regulatory agencies to finalize specific details for the pivotal phase II/III study
· PledPharma received US patent for method of treatment related to calmangafodipir
· CFO Yilmaz Mahshid has taken on a new external role and will be leaving PledPharma in September. Marie-Louise Alamaa has been appointed as interim CFO
Significant events after the reporting period
· Positive pre-clinical results with PledOx published in Antioxidants
· Marie Ekström Trägårdh  has chosen to step down from company’s Board of Directors due to personal reasons

Comments from the CEO
 PledOx POLAR program
In April, we took the decision to prematurely stop the clinical Phase III program POLAR with our lead candidate PledOx®, developed to provide patients that are treated adjuvantly or for metastatic colorectal cancer prevention against the nerve damage that can occur in conjunction with chemotherapy treatment. The decision was taken after a recommendation from the independent Drug Safety Monitoring Board (DSMB) to stop the program due to a few severe allergic reactions which has been observed in the studies after repeated dosing with study drug. Allergic hypersensitivity reactions are not uncommon in relation to platinum-based chemotherapy.
We will now concentrate on collecting the remaining data in the challenging COVID-19 environment and have targeted a data cut-off for the third quarter. The total Phase III data generated in the POLAR program will enable a thorough evaluation of the safety and efficacy and an assessment of the benefit/risk of PledOx. This evaluation will determine if further activities to find a path forward for PledOx to treat nerve damage associated with chemotherapy are motivated.

Continued scientific interest for PledOx
Despite this setback, we continue to gain interest for PledOx in the scientific community. In June, positive pre-clinical results with PledOx were presented as a poster at 2020 Annual Meeting of Peripheral Nerve Society (PNS). The preclinical oxaliplatin study confirms a protective effect of PledOx (calmangafodipir) against oxaliplatin-induced small fiber neuropathy. The administration of PledOx at the dose of 5 mg/kg prevents oxaliplatin-induced mechanical allodynia, cold hyperalgesia and reduction in intraepidermal nerve fiber density.
In early July, these pre-clinical results were also published in the peer-reviewed, open access journal Antioxidants. The article, titled Calmangafodipir Reduces Sensory Alterations and Prevents Intraepidermal Nerve Fibers Loss in a Mouse Model of Oxaliplatin Induced Peripheral Neurotoxicity, focuses on the protective effect against oxaliplatin-induced peripheral neuropathy at the pathological level, and the findings are in line with the behavioral results.

US patent related to calmangafodipir
In May, we received a US patent for method of treatment related to calmangafodipir, forming an additional protective layer around both PledOx and Aladote. The expiry date for the patent is July 2030. This is in addition to the already granted composition-of-matter patent of calmangafodipir with expiry date December 2032. We are pleased with the notice of allowance of our second patent application to further strengthen our robust patent portfolio.

Continued development of Aladote
Our focus on Aladote and the ongoing regulatory interactions and clinical study remains unchanged as Aladote represents an important opportunity to address the high unmet medical need following paracetamol intoxication. A Phase I/IIa Proof-of-Principle study has been successfully completed, and a pivotal phase II/III study with a single administration is under planning. It is reassuring that no severe allergic-hypersensitivity reactions have been reported after single administration in the clinical trials with calmangafodipir.
In order to continue the development of our clinical portfolio, we have a robust cash position of approximately 184 million SEK in cash and cash equivalents reported at the end of the second quarter 2020.

Changes in management team and Board
In late May, we announced that CFO Yilmaz Mahshid has decided to leave the company and take on the position as CEO of Medivir. I have worked closely with Yilmaz during an intense period for the company, and I am very grateful for his commitment and professionalism. I wish him the best of success with his future commitments. In June, we named Marie-Louise Alamaa as the new interim CFO at PledPharma. She has extensive experience within finance and controlling from public companies, and she will make an excellent addition to the team. After the period, Board member Marie Ekström Trägårdh announced that she has decided to step down from the company's Board of Directors due to personal reasons.
Despite the global COVID-19 pandemic data collection for the POLAR phase III program is progressing according to plan with a data cut-off targeted for the third quarter 2020. We are grateful for the commitments of participating patients and investigating sites for this achievement. In these uncertain and unsettling times, our focus on Aladote and the ongoing regulatory interactions and clinical study remains firm. I look forward to relaying news to you around the planned study, as well as the data from the POLAR program.

Nicklas Westerholm, CEO
PledPharma AB, Stockholm